Predictive and prognostic value of aurora kinase A combined with tumor-infiltrating lymphocytes in medullary thyroid carcinoma

被引:0
作者
Wang, Zhongyu [1 ]
Guo, Fengli [1 ,2 ]
Fu, Guiming [1 ,3 ]
Zhao, Zewei [1 ]
Kang, Ning [1 ]
Hou, Xiukun [1 ]
Zheng, Xiangqian [1 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Dept Thyroid & Neck Tumor,Tianjins Clin Res Ctr C, Tianjin 300060, Peoples R China
[2] Binzhou Med Univ Hosp, Dept Thyroid & Breast Surg, Binzhou, Peoples R China
[3] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Clin Res Ctr Canc, Sichuan Canc Ctr,Affiliated Canc Hosp, Chengdu, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
基金
中国国家自然科学基金;
关键词
aurora kinase A; tumor-infiltrating lymphocyte; medullary thyroid carcinoma; structural recurrence; biochemical recurrence; CANCER; IDENTIFICATION; GUIDELINES; MANAGEMENT; DIAGNOSIS; IMPACT;
D O I
10.3389/fonc.2024.1379420
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Aurora kinase A (AURKA) and tumor-infiltrating lymphocytes (TILs) are both known to play an essential role in tumorigenesis. However, the expression and prognostic value of the AURKA and TILs in medullary thyroid carcinoma (MTC) have not yet been investigated. Patients and methods: Surgical specimens and clinical data of 137 patients diagnosed with MTC were collected. AURKA expression and TILs infiltration were quantified by immunohistochemistry and hematoxylin-eosin staining. Subsequently, the prognostic value of AURKA expression and TIL infiltration in MTC was evaluated. Results: AURKA was highly expressed in patients with multifocal tumor, cervical lymph node metastasis, and an advanced TNM stage, indicating a high probability of recurrence. AURKA further exhibited a positive correlation with TILs (R = 0.44, P < 0.001). High expression of AURKA combined with a low numbers of TILs (AURKA(high)/TILs(low)) was identified as an independent prognostic factor for biochemical recurrence (odds ratio: 4.57, 95% confidence interval: 1.54-14.66, P < 0.01) and recurrence-free survival (hazard ratio: 3.64, 95% confidence interval: 1.52-8.71, P < 0.001). The combination of AURKA and TILs apparently improves the prognostic value for biochemical recurrence (area under the curve: 0.751) and structural recurrence (area under the curve: 0.836) of MTC. Notably, AURKA(high)/TILs(low) demonstrated a high value for prediction of distant or unresectable locoregional recurrence, with an overall accuracy of 86.9%. Conclusion: AURKA(high) is associated with the MTC malignancy. The combination of AURKA(high)/TILs(low) was identified as novel independent prognostic marker in MTC, predicting incurable disease recurrence with high accuracy.
引用
收藏
页数:12
相关论文
共 48 条
  • [1] Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
    Aftimos, Philippe
    Oliveira, Mafalda
    Irrthum, Alexandre
    Fumagalli, Debora
    Sotiriou, Christos
    Gal-Yam, Einav Nili
    Robson, Mark E.
    Ndozeng, Justin
    Di Leo, Angelo
    Ciruelos, Eva M.
    de Azambuja, Evandro
    Viale, Giuseppe
    Scheepers, Elsemieke D.
    Curigliano, Giuseppe
    Bliss, Judith M.
    Reis-Filho, Jorge S.
    Colleoni, Marco
    Balic, Marija
    Cardoso, Fatima
    Albanell, Joan
    Duhem, Caroline
    Marreaud, Sandrine
    Romagnoli, Dario
    Rojas, Beatriz
    Gombos, Andrea
    Wildiers, Hans
    Guerrero-Zotano, Angel
    Hall, Peter
    Bonetti, Andrea
    Larsson, Karolina Fs
    Degiorgis, Martina
    Khodaverdi, Silvia
    Greil, Richard
    Sverrisdottir, Asgerdur
    Paoli, Marta
    Seyll, Ethel
    Loibl, Sibylle
    Linderholm, Barbro
    Zoppoli, Gabriele
    Davidson, Nancy E.
    Johannsson, Oskar Th
    Bedard, Philippe L.
    Loi, Sherene
    Knox, Susan
    Cameron, David A.
    Harbeck, Nadia
    Montoya, Maite Lasa
    Brandao, Mariana
    Vingiani, Andrea
    Caballero, Carmela
    [J]. CANCER DISCOVERY, 2021, 11 (11) : 2796 - 2811
  • [2] The local inflammatory response in colorectal cancer - Type, location or density? A systematic review and meta-analysis
    Alexander, Peter G.
    McMillan, Donald C.
    Park, James H.
    [J]. CANCER TREATMENT REVIEWS, 2020, 83
  • [3] AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol
    Anand, S
    Penrhyn-Lowe, S
    Venkitaraman, AR
    [J]. CANCER CELL, 2003, 3 (01) : 51 - 62
  • [4] Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT
    Baldini, Enke
    Arlot-Bonnemains, Yannick
    Sorrenti, Salvatore
    Mian, Caterina
    Pelizzo, Maria R.
    De Antoni, Enrico
    Palermo, Silvio
    Morrone, Stefania
    Barollo, Susi
    Nesca, Angela
    Moretti, Costanzo G.
    D'Armiento, Massimino
    Ulisse, Salvatore
    [J]. BMC CANCER, 2011, 11
  • [5] Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
    Beatty, Gregory L.
    Gladney, Whitney L.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (04) : 687 - 692
  • [6] Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
    Carvajal-Hausdorf, Daniel
    Altan, Mehmet
    Velcheti, Vamsidhar
    Gettinger, Scott N.
    Herbst, Roy S.
    Rimm, David L.
    Schalper, Kurt A.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [7] IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
    Chan, Li-Chuan
    Li, Chia-Wei
    Xia, Weiya
    Hsu, Jung-Mao
    Lee, Heng-Huan
    Cha, Jong-Ho
    Wang, Hung-Ling
    Yang, Wen-Hao
    Yen, Er-Yen
    Chang, Wei-Chao
    Zha, Zhengyu
    Lim, Seung-Oe
    Lai, Yun-Ju
    Liu, Chunxiao
    Liu, Jielin
    Dong, Qiongzhu
    Yang, Yi
    Sun, Linlin
    Wei, Yongkun
    Nie, Lei
    Hsu, Jennifer L.
    Li, Hui
    Ye, Qinghai
    Hassan, Manal M.
    Amin, Hesham M.
    Kaseb, Ahmed O.
    Lin, Xin
    Wang, Shao-Chun
    Hung, Mien-Chie
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (08) : 3324 - 3338
  • [8] Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcomaaEuro
    Dickson, M. A.
    Mahoney, M. R.
    Tap, W. D.
    D'Angelo, S. P.
    Keohan, M. L.
    Van Tine, B. A.
    Agulnik, M.
    Horvath, L. E.
    Nair, J. S.
    Schwartz, G. K.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (10) : 1855 - 1860
  • [9] Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Filetti, S.
    Durante, C.
    Hartl, D.
    Leboulleux, S.
    Locati, L. D.
    Newbold, K.
    Papotti, M. G.
    Berruti, A.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (12) : 1856 - 1883
  • [10] A PhaseIITrial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
    Gay, Carl M.
    Zhou, Yanhong
    Lee, J. Jack
    Tang, Xi Ming
    Lu, Wei
    Wistuba, Ignacio I.
    Ferrarotto, Renata
    Gibbons, Don L.
    Glisson, Bonnie S.
    Kies, Merrill S.
    Simon, George R.
    Heymach, John, V
    Tsao, Anne S.
    [J]. ONCOLOGIST, 2020, 25 (10) : E1457 - E1463